Llamas could help treat schizophrenia: study
They're known for their fluffy furs and sassy stares, but scientists have discovered that llamas may also be the key to treating schizophrenia.
And this isn't even the first time this year that llamas have been at the heart of curing a scary health issue.
Advertisement
They're known for their fluffy furs and sassy stares, but it turns out llamas may also be the key to treating schizophrenia.
Cavan for Adobe – stock.adobe.com
In a mind-blowing new study, French researchers have developed a molecule from llama antibodies that could one day help patients with schizophrenia overcome cognitive deficits — a major hurdle that existing treatments fail to address.
Scientists at the Institute of Functional Genomics in Montpellier have engineered what's called a nanobody — a tiny antibody fragment found in camelids like llamas — that can activate a specific glutamate receptor responsible for brain signaling.
What's more, this molecule can cross the blood-brain barrier — a major challenge in drug development — and go straight to work on neural receptors when injected via a vein or muscle.
Advertisement
Researchers tested the llama-derived nanobody in two preclinical models of schizophrenia.
Just one injection was enough to boost brainpower in mice, showing a clear and sustained improvement in cognitive function for up to a week.
More research will be needed to see if this presents a promising new avenue of treatment for schizophrenia and, if so, whether or not this can be expanded to treat other psychiatric and neurodegenerative diseases.
Advertisement
The findings were published Wednesday in the journal Nature.
Schizophrenia is a chronic mental disorder that affects how people perceive reality, leading to hallucinations, delusions, disorganized thinking and speech, paranoia and time gaps.
elnariz – stock.adobe.com
Schizophrenia is a chronic mental disorder that affects how people perceive reality, leading to hallucinations, delusions, disorganized thinking and speech, paranoia and time gaps.
More than 200,000 people in the US are living with schizophrenia, for which there is no cure.
Advertisement
The cause of schizophrenia is still unknown, but research suggests a combination of genetic and environmental factors are likely to encourage its onset, which typically occurs between the ages of 16 and 30.
Schizophrenia is primarily treated with antipsychotics, which target some of the more severe symptoms like hallucinations and delusions, but fail to do much for cognitive function.
This new study offers hope for repairing cognition, as opposed to simply managing symptoms.
'In humans obviously we don't know [yet], but in mice yes, it is sufficient to treat most deficits of schizophrenia,' paper author and CNRS molecular biologist Jean-Philippe Pin told Newsweek.
'For development as a therapeutic tool, more safety and bioavailability studies are needed. Production of large quantities of high quality must be set up to start human studies. For these two possibilities, either a company takes up our project or we find investors to create a startup company.'
Meanwhile, another study published last month found that llamas may also hold the secret weapon to curing COVID — and it's also in their nanobodies.
'This work provides a strong foundation for developing next-generation antibodies that could be vital in combating not only current but also future coronavirus threats,' said Dr. Xavier Saelens, senior author of the study and a principal investigator at the VIB-UGent Center for Medical Biotechnology in Belgium.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
39 minutes ago
- Yahoo
Genethon to Launch Pivotal Trial in Europe of GNT0004 a Low-Dose Microdystrophin Gene Therapy for Duchenne Muscular Dystrophy
Phase 3 trial clearance is based on the Phase 1/2 results demonstrating safety and efficacy of the 3x10¹³ vg/kg dose of microdystrophin, which is lower than doses used in other gene therapies for Duchenne muscular dystrophy (DMD). The double blind trial will be initiated in the UK and France beginning in August and September, and will enroll 64 boys aged 6 to 10 with DMD who have retained their walking ability. PARIS, July 28, 2025--(BUSINESS WIRE)--Genethon, a worldwide pioneer and leader in research and development in gene therapy for rare genetic diseases, has received approvals from regulatory authorities, MHRA and EMA*, to begin pivotal Phase 3 clinical trials in France and the UK of its gene therapy, GNT0004, for Duchenne muscular dystrophy (DMD). Genethon CEO Frederic Revah observed, "We are delighted to be able to continue these trials and are determined to bring GNT0004 to market for young patients and their families who are waiting for a therapeutic solution. This marks a decisive step forward for our gene therapy program for DMD, which began in 2021 and has demonstrated extremely promising results in the first children treated in the Phase1/2 portion of our Phase1/2/3 study." Dr. Revah added, "In addition to the very positive results in patients treated in the early phases, one of the strengths of our product is the dose selected for the pivotal phase, which is lower than those used in other gene therapy trials for DMD. Approvals of our Phase 3 trials reflect the regulatory authorities' confidence in GNT0004 as well as the work accomplished by our teams." The Phase 3 authorizations in Europe are based on the results of Phase 1/2 studies showing good tolerance of GNT0004 as well as efficacy in terms of microdystrophin expression, creatine phosphokinase (CPK) reduction, and motor function. Patients showed prolonged improvement or stabilization of motor functions and significant persistent reduction in CPK, a key marker of muscle damage. The Phase 3 double blind trials will begin in August and September in the UK and France using a single intravenous injection of GNT0004, which contains an optimized hMD1 transgene, a shortened (3x10¹³ vg/kg microdystrophin) but functional version of the gene encoding dystrophin in an AAV8 vector associated with transient immunological prophylactic treatment. The vector is designed to express itself in muscle tissue and the heart thanks to a Spc5-12 promoter sequence specific to these tissues. A total of 64 boys aged 6 to 10 with DMD who have retained their walking ability will be enrolled. * French ANSM as reporting member state for the EMA About Duchenne muscular dystrophy Duchenne muscular dystrophy is a rare progressive genetic disease that affects all the muscles in the body and mainly boys (1 in 5,000). It is caused by abnormalities in the gene responsible for the production of dystrophin, a structural protein essential for the stability of muscle fiber membranes and their metabolism. The absence of dystrophin leads to progressive degeneration of the skeletal and cardiac muscles, loss of walking and respiratory capacity, progressive heart failure, and death between the ages of 20 and 40. About Genethon A pioneer in the discovery and development of gene therapies for rare diseases, Genethon is a non-profit laboratory created by the AFM-Telethon. A first gene therapy drug, to which Genethon contributed, has been approved for marketing for spinal muscular atrophy. With more than 240 scientists and experts, Genethon's goal is to develop innovative therapies that change the lives of patients suffering from rare genetic diseases. Thirteen gene therapy products developed by Genethon or to which Genethon has contributed are currently undergoing clinical trials for diseases of the liver, blood, immune system, muscles, and eyes. Seven other products are in preparation for clinical trials over the next five years. View source version on Contacts Press contact:Marion Delbouis/Stéphanie Bardon – communication@ / +33 (0)6 45 15 95 87 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Scientific American
2 hours ago
- Scientific American
First-Ever Antimatter Qubit Could Help Crack Cosmic Mysteries
Physicists have created a quantum bit, or qubit, the fundamental storage unit of a quantum computer, out of antimatter for the first time. The researchers used magnetic fields to trap a single antiproton—the antimatter version of the protons inside of atoms—and measured how fast its spin changed direction for almost a full minute. The findings were published on July 23 in the journal Nature. Quantum computers made of antimatter qubits are still a long way off and would be much harder to build than matter quantum computers—which are already extremely tricky. The feat is exciting, however, because of what such antimatter experiments could reveal about the universe itself. A particle's spin can be in a state of 'up' or 'down,' just like a computer bit can take on a state of '0' or '1.' But where a classical bit must be in either of the latter two states, the antiproton qubit's spin could be up, down or any combination of both at the same time. This fantastical ability of qubits is what sets them apart from classical bits and promises that quantum computers will one day offer incredible improvements in calculation speed and ability compared with today's computers. On supporting science journalism If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today. The experiment demonstrated an unprecedented level of control over antimatter, says physicist Vincenzo Vagnoni of the Italian National Institute of Nuclear Physics (INFN), who was not involved in the experiment. 'This is thanks to [the researchers'] development of highly efficient antiproton magnetic traps, which can keep antiprotons 'alive' without them annihilating with matter. While we are still far from the curvature engines of the Star Trek saga, this is the closest thing to them that has been developed on Earth so far,' Vagnoni says, referring to the science-fiction franchise's warp drive engines fueled by antimatter. Setting sci-fi aspirations aside, the achievement could help physicists solve the mystery of why the universe is dominated by matter and not antimatter—in other words, why the universe around us exists at all. 'If you are just looking into the physics, there's absolutely no reason why there should be more matter than antimatter,' says Stefan Ulmer, a physicist at CERN, the European laboratory for particle physics near Geneva, and spokesperson for its Baryon Antibaryon Symmetry Experiment (BASE). Yet there is almost no antimatter in the cosmos, whereas matter is abundant. 'The big motivation for these experiments is: we are looking for the reason why there might be a matter-antimatter asymmetry,' Ulmer says. One potential reason could be a difference between the proton and the antiproton in a property called the magnetic moment. Protons and antiprotons have electric charge—the proton's charge is positive, and the antiproton's is negative. These charges make the particles act like little bar magnets that point in different directions depending on the orientation of their spin. The strength and orientation of the magnet is called the particle's magnetic moment. If it turns out that the magnetic moments of protons and antiprotons are not the same, that could explain why matter won out over antimatter in the universe. So far, measurements have found no difference between the two to an accuracy of 1.5 parts in a billion. But scientists had never before been able to measure the oscillation of the magnetic moment of single protons or antiprotons—or of any other fundamental particles. Similar previous experiments only measured the phenomenon in ions or charged atoms. 'We can now have full control over the spin state of a particle,' says the new study's lead author Barbara Latacz of CERN and the RIKEN Advanced Science Institute in Japan. 'For fundamental physicists, it's a super exciting opportunity.' The researchers hope to use the technique to improve the precision of the measurement of the magnetic moment in protons and antiprotons by a factor of 25. If they ever discover a difference or find some other discrepancy between matter and antimatter, then antimatter quantum computers could become worth building, despite the difficulty. 'If there is any surprise in matter-antimatter asymmetry, it could be interesting to do basically the same calculations with matter qubits and antimatter qubits and compare the results,' says Ulmer, who is also based at RIKEN.
Business Wire
2 hours ago
- Business Wire
Genethon to Launch Pivotal Trial in Europe of GNT0004 a Low-Dose Microdystrophin Gene Therapy for Duchenne Muscular Dystrophy
PARIS--(BUSINESS WIRE)--Genethon, a worldwide pioneer and leader in research and development in gene therapy for rare genetic diseases, has received approvals from regulatory authorities, MHRA and EMA*, to begin pivotal Phase 3 clinical trials in France and the UK of its gene therapy, GNT0004, for Duchenne muscular dystrophy (DMD). Genethon CEO Frederic Revah observed, 'We are delighted to be able to continue these trials and are determined to bring GNT0004 to market for young patients and their families who are waiting for a therapeutic solution. This marks a decisive step forward for our gene therapy program for DMD, which began in 2021 and has demonstrated extremely promising results in the first children treated in the Phase1/2 portion of our Phase1/2/3 study.' Dr. Revah added, 'In addition to the very positive results in patients treated in the early phases, one of the strengths of our product is the dose selected for the pivotal phase, which is lower than those used in other gene therapy trials for DMD. Approvals of our Phase 3 trials reflect the regulatory authorities' confidence in GNT0004 as well as the work accomplished by our teams.' The Phase 3 authorizations in Europe are based on the results of Phase 1/2 studies showing good tolerance of GNT0004 as well as efficacy in terms of microdystrophin expression, creatine phosphokinase (CPK) reduction, and motor function. Patients showed prolonged improvement or stabilization of motor functions and significant persistent reduction in CPK, a key marker of muscle damage. The Phase 3 double blind trials will begin in August and September in the UK and France using a single intravenous injection of GNT0004, which contains an optimized hMD1 transgene, a shortened (3x10¹³ vg/kg microdystrophin) but functional version of the gene encoding dystrophin in an AAV8 vector associated with transient immunological prophylactic treatment. The vector is designed to express itself in muscle tissue and the heart thanks to a Spc5-12 promoter sequence specific to these tissues. A total of 64 boys aged 6 to 10 with DMD who have retained their walking ability will be enrolled. * French ANSM as reporting member state for the EMA About Duchenne muscular dystrophy Duchenne muscular dystrophy is a rare progressive genetic disease that affects all the muscles in the body and mainly boys (1 in 5,000). It is caused by abnormalities in the gene responsible for the production of dystrophin, a structural protein essential for the stability of muscle fiber membranes and their metabolism. The absence of dystrophin leads to progressive degeneration of the skeletal and cardiac muscles, loss of walking and respiratory capacity, progressive heart failure, and death between the ages of 20 and 40. About Genethon A pioneer in the discovery and development of gene therapies for rare diseases, Genethon is a non-profit laboratory created by the AFM-Telethon. A first gene therapy drug, to which Genethon contributed, has been approved for marketing for spinal muscular atrophy. With more than 240 scientists and experts, Genethon's goal is to develop innovative therapies that change the lives of patients suffering from rare genetic diseases. Thirteen gene therapy products developed by Genethon or to which Genethon has contributed are currently undergoing clinical trials for diseases of the liver, blood, immune system, muscles, and eyes. Seven other products are in preparation for clinical trials over the next five years.
